口服抗凝增加保守治疗B型主动脉夹层晚期主动脉干预风险(ORCA研究)
单中心回顾性队列研究纳入2003年1月1日至2020年12月31日保守治疗的急性B型主动脉夹层患者69例,中位随访49.3个月,47例(68%)随访期间接受口服抗凝。口服抗凝与更多晚期主动脉事件相关(HR 3.94,95%CI 1.06-14.6,P=0.040)。作者认为B型主动脉夹层不应作为口服抗凝的主要指征,因其他指征抗凝者需频繁随访影像。
要点
- 保守治疗的B型主动脉夹层患者中,口服抗凝与晚期主动脉事件风险升高相关(HR 3.94)。
- 晚期主动脉事件发生28例(41%),包括干预27例(39%)和破裂1例(1%)。
- 作者认为B型主动脉夹层不应作为口服抗凝的主要指征。
核心结论
- 数据提示口服抗凝治疗与晚期主动脉干预风险增加相关。
- B型主动脉夹层不应作为口服抗凝的主要指征,因其他指征口服抗凝的患者需要频繁随访影像。
研究设计与样本
- 单中心回顾性队列研究,纳入2003年1月1日至2020年12月31日高容量血管中心的合格患者。
- 排除A型或非A非B夹层、孤立性腹主动脉夹层、壁内血肿和结缔组织病患者。
- 共纳入69例患者,男性50例,中位年龄65岁(四分位距58-72岁)。
- 中位随访49.3个月(28-92个月)。
主要发现
- 47例(68%)在随访期间任何时间接受口服抗凝,中位时长26个月(11-61个月)。
- 晚期主动脉事件发生于28例(41%),包括干预27例(39%)和破裂1例(1%)。
- 口服抗凝与更多晚期主动脉事件相关(HR 3.94,95%CI 1.06-14.6,P=0.040)。
- 次要结局与口服抗凝无关联。
关键数值与推荐
- 主要结局为免于晚期主动脉事件(干预、破裂和死亡)。
- 次要结局包括脊髓缺血、出血、肾内脏动脉闭塞、髂股干预、夹层进展、主动脉增长、主动脉重塑、假腔血栓形成恶化以及30天和总体死亡率。
- 采用多变量Cox比例风险模型分析事件时间,口服抗凝作为时变协变量,死亡作为竞争风险,并调整潜在混杂因素。
临床怎么用
- 作者认为B型主动脉夹层不应作为口服抗凝的主要指征。
- 作者指出因其他指征口服抗凝的患者需要频繁随访影像。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Single-center retrospective cohort study to evaluate the impact of oral anticoagulation (OAC) on long-term outcomes of conservatively managed acute type B aortic dissection. METHODS: Clinical and morphological data of eligible patients from a high-volume vascular centre from 1 January 2003 through 31 December 2020 were evaluated. Patients were excluded for: type A or non-A-non-B dissection, isolated abdominal dissection, intramural haematoma and connective tissue disease. The primary outcome was freedom from late aortic events (intervention, rupture and mortality). Secondary outcomes included spinal cord ischaemia, bleeding, reno-visceral artery occlusion, ilio-femoral intervention, dissection propagation, aortic growth, aortic remodelling, deterioration of false lumen thrombosis as well as 30-day and overall mortality. Time to event was analysed using multivariable Cox proportional hazard models with OAC as time-varying covariate and mortality as a competing risk. The impact of OAC was adjusted for potential confounding factors. RESULTS: A total of 69 patients [50 males, median age 65 (interquartile range: 58-72) years] were enrolled. The median follow-up was 49.3 (28-92) months. A total of 47 patients (68%) received OAC at any time throughout the follow-up for a median length of 26 (11-61) months. Late aortic events occurred in 28 patients (41%) including intervention (n = 27, 39%) and rupture (n = 1, 1%). OAC was associated with more late aortic events (hazard ratio 3.94, 95% confidence interval 1.06-14.6, P = 0.040). Secondary outcomes were not associated with OAC. CONCLUSIONS: Our data suggest a relation of OAC therapy with an increased risk for late aortic interventions. Type B aortic dissection should not be the primary indication for OAC and patients with OAC for other indications require frequent follow-up imaging.
引用
- Jesse K, Meuli L, Kopp R, et al. ORal anticoagulation risks late aortic intervention in Conservatively managed type B Aortic dissection (ORCA study). Eur J Cardiothorac Surg. 2022. PMID: 36200847. doi:10.1093/ejcts/ezac495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。